177
Xu J#, Huang C#, Fan G#, Liu Z#, Shang L, Zhou F, Wang Y, Yu J, Yang L, Xie K, Huang Z, Huang L, Gu X, Li H, Zhang Y, Wang Y, Hayden F G, Horby P W, Cao B*, Wang C*. Use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front. Med., [online ahead of print] doi: 10.1007/s11684-020-0800-y
178
Jiuyang Xu#, Jiapei Yu, Luning Yang, Fei Zhou, Hui Li, Bin Cao*. Influenza Virus in Community-Acquired Pneumonia: Current Understanding and Knowledge Gaps. Semin Respir Crit Care Med 2020;00:1–13.DOI:https://doi.org/10.1055/s-0040-1710584.
179
Jiuyang Xu#,Jiapei Yu,Luning Yang,Fei Zhou,Hui Li,Bin Cao*.Influenza Virus in Community-Acquired Pneumonia:Current Understanding and Knowledge Gaps.Semin Respir Crit Care Med 2020;00:1–13.DOI:https://doi.org/10.1055/s-0040-1710584.
180
Yeming Wang#, Dingyu Zhang#, Guanhua Du#, Ronghui Du#, Jianping Zhao#, Yang Jin#, Shouzhi Fu#, Ling Gao#, Zhenshun Cheng#, Qiaofa Lu#,Yi Hu#, Guangwei Luo#,Bin Cao*, Chen Wang*.Remdesivir in adults with severe COVID-19: a randomised,double-blind, placebo-controlled, multicentre trial.The Lancet,Published Online April 29, 2020,DOI:https://doi.org/10.1016/S0140-6736(20)31022-9
181
Hui Li#, Liang Liu#, Dingyu Zhang#, Jiuyang Xu, Huaping Dai, Nan Tang, Xiao Su, Bin Cao*.SARS-CoV-2 and viral sepsis: observations and hypotheses.The Lancet,Published Online,April 17, 2020,DOI:https://doi.org/10.1016/S0140-6736(20)30920-X
182
Jiankang Zhao#,Chao Liu,Yingmei Liu,Yulin Zhang,Zhujia Xiong,Yanyan Fan,Xiaohui Zou,Binghuai Lu,Bin Cao*. Genomic characteristics of clinical important ST11 Klebsiella pneumoniaeworldwide. Journal of Global Antimicrobial Resistance, Available online 8 April 2020.DOI: https://doi.org/10.1016/j.jgar.2020.03.023.
183
Chen W#, Sun L#, Guo L, Cao B, Liu Y, Zhao L, Lu B, Li B, Chen J*, Wang C*. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli. Ann Transl Med. 2020 Feb;8(3):39. doi: 10.21037/atm.2019.10.40.
184
Cao B#*, Wang Y#, Wen D#, Liu W#, Wang J#, Fan G#, Ruan L#, Song B#, Cai Y#, Wei M#, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D*, Wang C*.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med. 2020 Mar 18.
185
Fei Zhou#, Ting Yu#, Ronghui Du#, Guohui Fan#, Ying Liu#, Zhibo Liu#, Jie Xiang#, Hua Chen*, Bin Cao*.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet 2020 Published online March 9, 2020,DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
186
Xiao jing Cui#,Lei Gao#,Bin Cao*.Management of Latent Tuberculosis Infection in China: Exploring solutions suitable for high-burden countries.International Journal of Infectious Diseases,Available online 27 February 2020.DOI:https://doi.org/10.1016/j.ijid.2
187
Zhang Y, Xu J, Li H, Cao B, A novel coronavirus (COVID-19) outbreak: a call for action, CHEST (2020), doi: https://doi.org/10.1016/j.chest.2020.02.014.
188
Gu XY#, Cao B*, Wang JW. Full spectrum of 2019-nCoV disease severity still being depicted. Lancet 2020 February 14,DOI:https://doi.org/10.1016/S0140-6736(20)30371-8
189
Shang LH#, Zhao JP, Hu Y, Du RH, Cao B*. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; published online Feb. DOI: https://doi.org/10.1016/ S0140-6736(20)30361-5
190
Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. 2020 Feb 15;201(4):P7-P8. doi: 10.1164/rccm.2014P7.
191
Wang Y#, Fan G#, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B*; CAP-China Network. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis. 2019 Dec 11. pii: jiz656. doi: 10.1093/infdis/jiz656. [Epub ahead of print]
192
徐九洋#, 曹彬*. 瑞德西韦治疗新型冠状病毒肺炎患者临床试验在武汉启动. 中华结核和呼吸杂志,2020,43( 03 ): E011-E011. DOI: 10.3760/cma.j.issn.1001-0939.2020.0011
